Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Apoptotic Signalling and Human Tissue Markers: Full Evidence Review

Previous related pageVitamin D, Apoptotic Signalling and Human Tissue Markers: Study SummaryNext related pageVitamin D, Apoptotic Signalling and Human Tissue Markers: Study Summary
Study at a glance

How was vitamin D studied in controlled cell death?

This review examines apoptosis, a regulated process through which cells are removed. Studies tested vitamin D-related compounds in thyroid-cancer cells and injured mouse skin. A human trial measured proteins linked with apoptosis in normal bowel tissue from people with a history of bowel growths called adenomas. These studies measured different processes and outcomes.

Did vitamin D have the same effect on cancer cells and injured skin?

Calcitriol, the active vitamin D hormone, made the tested thyroid-cancer cells more likely to die in response to the drug doxorubicin. Experiments changing selected signalling components supported a possible mechanism. This was not a trial of cancer treatment in patients. In mice injured by ultraviolet light, injected vitamin D precursor instead accompanied less injury and less damage involving broken DNA. The direction depended on the biological setting.

Did vitamin D change cell-death proteins in human bowel tissue?

An analysis of tissue samples from 104 participants examined tissue markers after one year of being assigned to vitamin D and calcium groups. Vitamin D did not clearly change the two apoptosis-related proteins studied or their ratio. These proteins describe part of the system that controls cell death; they do not count completed cell deaths or show that potentially cancerous cells were selectively removed.

Do these cell-death studies show benefits for cancer treatment or prevention?

Cell experiments and mouse injections are different from ordinary vitamin D3 supplements. The human tissue-sample study had small, unequal groups and did not measure cancer prevention through these markers. No clear marker change does not prove that every possible effect is absent. Together, the studies do not establish a universal increase or decrease in cell death, a cancer-prevention benefit or a reason to alter treatment.

Read the full article below ↓

Vitamin D-related signalling can change programmed cell death in experimental systems, but the direction depends on which cells are being studied and what they are experiencing. Sensitising tumour cells to a drug is a different biological task from protecting injured skin. A human colorectal trial adds another important boundary: changes proposed from laboratory work were not confirmed in its apoptosis-marker comparisons. This review separates those mechanistic and human questions rather than treating them as one disease-prevention claim. Vitamin D, Apoptotic Signalling and Human Tissue Markers: Study Summary.

Programmed cell death and apoptotic signalling

Apoptosis is a regulated process through which cells are removed. Its value depends on context. Removing a damaged or unwanted cell can support tissue organisation, while excessive loss of functioning cells can worsen injury. A finding that vitamin D promotes apoptosis is therefore incomplete without identifying the cell type, exposure and outcome. The general physiology is introduced in Vitamin D and Apoptosis.

Researchers can study different parts of the process. Annexin-V measurements and cleaved-caspase assays provide evidence closer to an apoptotic response than measuring the abundance of a single regulatory protein. Even these assays need to be interpreted within their experimental design. A protein associated with susceptibility to death does not tell us how many cells actually died, and a DNA-fragmentation stain does not fully identify the pathway that produced it.

The selected evidence contains three different levels: perturbation of a signalling pathway in cultured thyroid-cancer cells, injury-associated DNA fragmentation in mouse skin, and apoptosis-related protein markers in human colorectal biopsies. Their endpoints should remain separate. Combining them into a statement that vitamin D “removes unhealthy cells” would imply a specificity and clinical benefit that none of these designs establishes.

Calcitriol and drug-associated death in thyroid-cancer cells

Zhang and colleagues studied K1 and IHH4 papillary thyroid carcinoma cells. A central protocol exposed cells to 100 nanomolar calcitriol for forty-eight hours, followed by 100 nanomolar doxorubicin for twenty-four hours. The question was whether calcitriol changed the cells’ response to the drug, not whether ordinary dietary vitamin D prevented cancer.

The combined experimental setting increased apoptosis-associated findings, including Annexin-V and cleaved-caspase-3 readouts. The investigators also examined a pathway involving the vitamin D receptor, PTPN2 and phosphorylated STAT3. Receptor and PTPN2 knockdown, together with STAT3-related perturbation, supplied stronger mechanistic evidence than an expression comparison alone.

Calcitriol increased VDR and PTPN2 and reduced phosphorylated STAT3. PTPN2 is an enzyme that removes phosphate groups from proteins, while STAT3 transmits signals involved in growth and survival. These findings supported a route by which calcitriol altered the signalling environment relevant to the drug response. This is a more specific conclusion than saying that calcitriol directly kills every cancer cell. It keeps the compound, timing, tumour-cell setting and co-treatment attached to the result.

The receptor dependence also illustrates why Vitamin D Receptors matters to interpretation. A response can depend on the receptor in a particular cell model without occurring uniformly across tissues. The presence of a receptor elsewhere does not establish that the same downstream pathway is active or that the same exposure is achievable or useful clinically. Regulation at the gene and signalling level, discussed in Vitamin D and Gene Expression, requires tissue-specific experimental support.

Strengths and limits of the pathway evidence

Using two cell lines and perturbing proposed pathway components made the study more informative than a single marker association. However, the experiments were small, with three experiments reported for key comparisons. Cell-line work cannot reproduce drug distribution, metabolism, tumour heterogeneity or toxicity in a person. An imperfect description of one lentiviral phosphorylated-STAT3 intervention also limits how cleanly that component can be interpreted.

The paper included eighty paired patient tissue samples. Those samples helped describe associations in human tumours and adjacent tissue; they did not test calcitriol plus doxorubicin as a treatment in patients. Human origin does not automatically make a comparison a clinical efficacy study. The distinction between an association and an intervention is central to Correlation vs Causation in Vitamin D.

Other phosphatase, STAT and cell-cycle findings further constrain a simple one-pathway account. A perturbation can change more than one process, and reduced growth is not automatically identical to increased apoptosis. The appropriate interpretation is that calcitriol sensitised the tested tumour cells to drug-associated apoptosis under the experimental conditions. It does not establish treatment benefit, a prescribing regimen or a reason to modify chemotherapy.

Protection from injury can involve less cell loss

Das and colleagues provide a different context. In ultraviolet B-injured mouse skin, injected 25-hydroxyvitamin D was associated with less tissue injury and reduced TUNEL-positive damage. TUNEL identifies DNA fragmentation; it is useful evidence of injury-associated cell damage but is not a complete map of apoptotic signalling.

The work focused on autophagy and macrophage-associated inflammatory responses. In cultured macrophages, the investigators used calcitriol. In mice, myeloid Atg7 deletion weakened the apparent protective effect. This supports involvement of a cellular recycling pathway in the injury response, but it does not prove an exclusively macrophage-specific mechanism because the targeting includes other myeloid cells.

The contrast with the thyroid-cell experiment is instructive. In one setting, increasing susceptibility to a cytotoxic drug was the measured outcome. In another, reducing injury-associated DNA fragmentation accompanied tissue protection. These are different biological tasks rather than evidence that one experiment must be wrong. Vitamin D and Skin supplies the tissue context, while Vitamin D and Inflammatory Signalling helps explain why immune responses and cell damage can change together.

The skin study cannot establish that vitamin D directly switches off a particular apoptotic pathway in human skin. Its pharmacological autophagy inhibitor was not perfectly specific, M1/M2 labels simplify immune-cell states, and the human biopsy signal for LC3/CD163 was not significant. Those biopsies also reused an earlier trial cohort, so they are not an independent clinical replication. Neither the injected mouse metabolite nor the cultured-cell hormone exposure should be described as an oral vitamin D3 treatment protocol for people.

Tissue homeostasis and disease prevention

The second question concerns translation: does altering apoptosis-related biology produce better tissue maintenance or prevent disease in humans? A mechanistic possibility is not enough. A useful clinical inference requires an intervention, an appropriate comparison and an outcome capable of demonstrating the claimed effect. Even a well-conducted marker study may leave prevention unresolved if it never measures disease incidence.

Gao and colleagues examined normal colorectal mucosa in people with a history of colorectal adenomas. Their biopsy substudy included 104 participants drawn from a larger 2,259-person trial. The intervention included vitamin D at 1,000 IU daily and calcium at 1,200 milligrams daily, with a partial factorial allocation. The biopsy analysis addressed changes over one year.

These are research exposures, not recommendations. The relevant point is that this study tested a human intervention and measured the proposed tissue markers, rather than inferring them from circulating vitamin D concentrations. At the same time, the biopsy subset was much smaller than the parent trial, and the allocation did not create four equally sized, fully interchangeable groups.

What Bax and Bcl2 can tell us

Bax and Bcl2 are commonly used to investigate the balance of apoptosis-related signalling. Their abundance and ratio can suggest changes in the regulatory environment. They do not count completed apoptotic events, and they do not demonstrate that an intervention preferentially removed cells that would otherwise become malignant.

In the vitamin D comparisons, Bax, Bcl2 and the Bax-to-Bcl2 ratio did not show significant effects. The reported relative effect for Bax was 0.97, with a 95% confidence interval from 0.68 to 1.38 and a p value of 0.86. The estimate was close to no difference, while the interval reflected uncertainty in both directions. It should not be presented as evidence of a beneficial increase.

An earlier positive Bax finding was not reproduced in this analysis. That comparison is useful background, but the earlier study is not counted here as a separately verified source supporting a new prevention conclusion. The selected human evidence is the null marker result and its limitations. Related analyses from the same participants do not constitute independent trials.

Why the null result matters without proving equivalence

The study weakens a confident claim that the tested supplementation reliably improves these apoptosis markers in this population over one year. It does not prove that vitamin D can never influence apoptosis under any circumstances. The confidence interval, small and unequal groups, biopsy selection, baseline imbalances and multiple outcomes all limit the precision and generalisability of the result.

Nor does the result establish a cancer-prevention effect in either direction. The markers are not disease-incidence endpoints. Even if a marker had changed significantly, an additional inferential step would remain between that change and prevention. Here, that first marker step was not demonstrated in the vitamin D comparisons.

This is an example of the distinction in Vitamin D Status vs Vitamin D Effect. A biological role for vitamin D, a circulating measurement and a response to supplementation are separate questions. The existence of receptor-mediated mechanisms in cultured cells cannot fill a missing human treatment effect. Equally, a null finding in a defined trial does not abolish the broader biology.

Homeostasis requires coordinated cell behaviour

Tissue maintenance depends on more than the rate of cell death. Cells also proliferate, specialise, change state and participate in repair. Vitamin D and Cell Differentiation addresses the development of specialised functions, while Vitamin D and Regeneration concerns renewal after loss or damage. Neither outcome can be inferred simply because an apoptotic marker moves in a preferred direction.

Persistent non-dividing cell states, discussed in Vitamin D and Cellular Senescence, are also distinct from completed apoptosis. A study that measures Bax does not establish that senescent cells have been removed. Keeping those processes separate prevents a plausible biological narrative from expanding beyond the measured evidence.

The present studies therefore answer complementary questions. The thyroid-cell experiment supports a defined drug-sensitisation mechanism. The skin experiment shows a protective injury context with less DNA-fragmentation-associated damage. The colorectal trial tests human markers and does not confirm the proposed supplementation effect. Their joint lesson is conditional regulation, not a universal push toward more or less cell death.

Conclusion

Vitamin D-related signalling can influence apoptotic responses in experimental settings, but the direction and meaning depend on cell type, injury and co-treatment. The selected human colorectal trial did not demonstrate significant changes in Bax, Bcl2 or their ratio, and it does not establish disease prevention through apoptosis. A sound interpretation preserves the difference between pathway evidence, tissue markers and clinical outcomes.

Original research

Das LM et al. 2019. Vitamin D improves sunburns by increasing autophagy in M2 macrophages. Autophagy. 15(5): 813. DOI: 10.1080/15548627.2019.1569298. PMID: 30661440.

Zhang T et al. 2020. Calcitriol enhances Doxorubicin-induced apoptosis in papillary thyroid carcinoma cells via regulating VDR/PTPN2/p-STAT3 pathway. Journal of cellular and molecular medicine. 24(10): 5629-5639. DOI: 10.1111/jcmm.15224. PMID: 32285621.

Gao Y et al. 2018. Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients. PloS one. 13(12): e0208762. DOI: 10.1371/journal.pone.0208762. PMID: 30557404.

Related reading

Library

The ERRα-VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR‐CYP24A1‐ERRα overexpression correlates with poor prognosis in patients with basal‐like breast cancer

Besides estrogen receptor alpha (ERα), estrogen‐related receptor alpha (ERRα) has also been shown to interfere with the VDR pathway, but its role in the antitumor and transactivation activity of calcitriol is completely unknown in breast cancer (BC).

Original paper ↗Read more →

Original sources

Source

Calcitriol enhances Doxorubicin‐induced apoptosis in papillary thyroid carcinoma cells via regulating VDR/PTPN2/p‐STAT3 pathway

The primary aim of this study was to investigate the role of Calcitriol on papillary thyroid carcinoma (PTC) and explore the possible mechanism.

Publication details

Zhang T et al. 2020. Calcitriol enhances Doxorubicin-induced apoptosis in papillary thyroid carcinoma cells via regulating VDR/PTPN2/p-STAT3 pathway. Journal of cellular and molecular medicine. 24(10): 5629-5639. DOI: 10.1111/jcmm.15224. PMID: 32285621.

Read more →
Source

Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients

Gao Y et al. 2018. Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients.

Publication details

Gao Y et al. 2018. Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients. PloS one. 13(12): e0208762. DOI: 10.1371/journal.pone.0208762. PMID: 30557404.

Read more →